EX-99.1 2 tv500227_ex99-1.htm EXHIBIT 99.1


Exhibit 99.1


Accelerate Diagnostics reports Q2 2018 financial results


Revenue up 142 Percent, Global install base up 25 Percent


TUCSON, Ariz., August 6, 2018 – Accelerate Diagnostics, Inc. today announced financial results for the quarter ending June 30, 2018. The company posted revenue of $1.7 million, up 142% from the prior year quarter, and reported a record number of new agreements signed in the quarter bringing the global total to 430 instruments. Contracts for customer evaluations total 312 instruments while commercial placements grew to 118 across the U.S., European, and Middle East regions.


“We’re excited to report a record number of new customer agreements this quarter,” said Lawrence Mehren, President and CEO. “While not yet fully translated into revenue, this sales momentum, strong customer advocacy, and upcoming clinical outcome data are quite encouraging.”


In addition, the company reported securing new agreements with prominent group purchasing organizations during the quarter. The agreements, covering approximately 1,400 hospitals, add additional value to member hospitals and aim to streamline the adoption process.


The company also announced progress on the development of its severe bacterial pneumonia kit including alignment with the U.S. Food and Drug Administration (FDA) on a shorter and less complex, 510(k) regulatory pathway, and clinical trial for the test. The expected start of the U.S. clinical trial is on or before our Q3 conference call.


Mr. Mehren, together with Steve Reichling, the company’s Chief Financial Officer, will host a conference call to review the financial results, commercial progress, and development updates at 4:15 p.m. Eastern Time on August 6, 2018.


Second quarter 2018 results


·Global install base increased by 25% during the quarter


·Net sales of $1.7 million for the second quarter and $2.5 million year to date, compared to $699 thousand and $1.2 million, for the same respective periods in the prior year


·Gross margin realized was 58% for the quarter and 52% year to date


·Selling, general, and administrative expenses for the quarter were $15.3M and $29.7M year to date as compared to $11.5M and $22.0M from the respective same periods in the prior year. These year-over-year increases were driven by higher personnel and customer evaluation related costs in the US and EU


·Research and development costs for the quarter were $6.1M and $12.9M year to date as compared to $5.5M and $9.8M from the respective same periods in the prior year. These year-over-year increases are the result of additional investments in the preparation for respiratory clinical trials and expanded scientific affairs activity


·Net loss of $23.2 million in the second quarter and $44.0 million year to date, or $0.43 and $0.80 per share on weighted average basic shares of 54.0 million and 54.8 million shares outstanding, respectively. This net loss includes $3.4 million in non-cash stock-based compensation expense in the second quarter and $9.0 million year to date.


·Net cash used in the quarter was $17.1 million, ending the quarter with total cash, investments, and cash-equivalents from all activities of $197.4 million


Full financial results for the quarter ending June 30, 2018 will be filed on Form 10-Q through the Securities and Exchange Commission’s (SEC) website at http://www.sec.gov. The company anticipates filing on August 7, 2018. Investors are cautioned not to place undue reliance on these preliminary and unaudited estimates in the event of material changes.





Audio Webcast and Conference Call


Listen to an audio webcast of the call by visiting the events section of the company’s investor relations website at ir.axdx.com. A replay of the audio webcast will be available until August 27, 2018.


To participate in the conference call, dial +1.877.883.0383 and enter the conference ID: 6994802


International participants may dial +1.412.902.6506. Please dial in 10-15 minutes prior to the start of the conference. A replay of the call will be available by telephone at +1.877.344.7529 (U.S.) or +1.412.317.0088 (international) using access code 10120739 until August 27, 2018.


About Accelerate Diagnostics, Inc.


Accelerate Diagnostics, Inc. (Nasdaq:AXDX), is an in vitro diagnostics company dedicated to providing solutions for the global challenges of sepsis, antibiotic resistance and healthcare-associated infections. Every 3-4 seconds someone dies from sepsis. In the United States, sepsis remains a leading cause of death, taking more lives than HIV, breast cancer, and prostate cancer combined. Bacteria are the most common cause of the serious infections that lead to sepsis, and continue to develop resistance to antibiotics. These antibiotic resistant bacteria further complicate the treatment approach for physicians who already wait days for lab results to determine which antibiotics are likely to be effective against the infection.


The Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for these infections. The FDA cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results within 7 hours direct from positive blood cultures. Recent external studies indicate the solution offers results 1-2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient days earlier.


The “ACCELERATE DIAGNOSTICS” and “ACCELERATE PHENO” and “ACCELERATE PHENOTEST” and diamond shaped logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.


For more information about the company, its products or technology, visit axdx.com.


Forward-Looking Statements


Certain of the statements made in this press release are forward looking, such as those, among others, about our projections as to when certain key business milestones may be achieved, the potential of our products or technology, the growth of the market, our estimates as to the size of our market opportunity and potential pricing, our competitive position and estimates of time reduction to results, and our future development plans and growth strategy. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Information about the risks and uncertainties faced by Accelerate Diagnostics is contained in the section captioned “Risk Factors” in the company’s most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission on March 1, 2018, and in any other reports that we file with the Securities and Exchange Commission from time to time. The company’s forward-looking statements could be affected by general industry and market conditions. Except as required by federal securities laws, the company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties or other contingencies.




Investors May Contact:

Laura Pierson, Accelerate Diagnostics, +1 520 365-3100, investors@axdx.com


Reporters May Contact:

Andrew Chasteen, Accelerate Diagnostics, +1 520 365-3100, achasteen@axdx.com


Source: Accelerate Diagnostics, Inc.








(in thousands)


   June 30,   December 31, 
   2018   2017 
Current assets:          
Cash and cash equivalents  $66,810   $28,513 
Investments   130,594    80,648 
Trade accounts receivable   1,823    1,946 
Inventory   11,317    8,063 
Prepaid expenses   1,421    850 
Other current assets   643    468 
Total current assets   212,608    120,488 
Property and equipment, net   5,443    4,890 
Intellectual property, net   124    134 
Other non-current assets   78     
Total assets  $218,253   $125,512 
Current liabilities:          
Accounts payable  $2,355   $2,080 
Accrued liabilities   5,302    3,636 
Deferred revenue and income   185    1,071 
Total current liabilities   7,842    6,787 
Other long term liabilities   26    21 
Convertible notes   115,499     
Total liabilities  $123,367   $6,808 
Commitments and contingencies          
Stockholders’ equity:          
Preferred shares, $0.001 par value; 5,000,000 preferred shares authorized and none outstanding as of June 30, 2018 and December 31, 2017        
Common stock, $0.001 par value; 75,000,000 common shares authorized with 54,090,575 shares issued and outstanding on June 30, 2018 and 75,000,000 authorized with 55,673,810 shares issued and outstanding on December 31, 2017   54    56 
Contributed capital   426,091    360,620 
Treasury Stock   (45,067)    
Accumulated deficit   (286,058)   (241,972)
Accumulated other comprehensive loss   (134)    
Total stockholders’ equity   94,886    118,704 
Total liabilities and stockholders’ equity  $218,253   $125,512 









(in thousands, except per share data)


   Three Months Ended   Six Months Ended 
   June 30,   June 30,   June 30,   June 30, 
   2018   2017   2018   2017 
Net sales  $1,692   $699   $2,493   $1,230 
Cost of sales   717    135    1,210    161 
Gross profit   975    564    1,283    1,069 
Costs and expenses:                    
Research and development   6,060    5,527    12,842    9,815 
Sales, general and administrative   15,330    11,460    29,682    21,988 
Total costs and expenses   21,390    16,987    42,524    31,803 
Loss from operations   (20,415)   (16,423)   (41,241)   (30,734)
Other income (expense):                    
Interest expense   (3,205)       (3,363)    
Foreign currency exchange (loss)   (253)   (7)   (198)   (33)
Interest income   774    153    1,075    290 
Other expense, net   (25)   (5)   (25)   (5)
Total other income (expense), net   (2,709)   141    (2,511)   252 
Net loss before income taxes   (23,124)   (16,282)   (43,752)   (30,482)
Provision for income taxes   (101)   (175)   (285)   (175)
Net loss  $(23,225)  $(16,457)  $(44,037)  $(30,657)
Basic and diluted net loss per share  $(0.43)  $(0.31)  $(0.80)  $(0.58)
Weighted average shares outstanding   54,003    53,568    54,821    52,732 
Other comprehensive loss:                    
Net loss  $(23,225)  $(16,457)  $(44,037)  $(30,657)
Net unrealized (loss) gain on available-for-sale investments   (2)   3    (55)   3 
Foreign currency translation adjustment   (191)   204    (79)   204 
Comprehensive loss  $(23,418)  $(16,250)  $(44,171)  $(30,450)









(in thousands)


   Six Months Ended 
   June 30,   June 30, 
   2018   2017 
Cash flows from operating activities:          
Net loss  $(44,037)  $(30,657)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation   1,072    1,045 
Amortization of intangible assets   10    6 
Amortization of investment discount   (146)   219 
Equity-based compensation   9,011    7,450 
Amortization of debt discount and issuance costs   2,273     
Loss on disposal of property and equipment   266    5 
(Increase) decrease in assets:          
Accounts receivable   123    (648)
Inventory   (3,138)   (5,537)
Prepaid expense and other   (444)   (624)
Other current assets   (175)   (313)
Other non-current assets   (78)    
Increase (decrease) in liabilities:          
Accounts payable   206    528 
Accrued liabilities   661    392 
Accrued Interest   1,105     
Deferred revenue and income   (935)   43 
Deferred compensation   5     
Net cash used in operating activities   (34,221)   (28,091)
Cash flows from investing activities:          
Purchases of equipment   (1,898)   (1,643)
Purchases of available-for-sale securities   (91,272)   (39,342)
Sales of available-for-sale securities   3,000    6,522 
Maturity of available-for-sale securities   38,272    18,449 
Net cash used in investing activities   (51,898)   (16,014)
Cash flows from financing activities:          
Issuance of common stock net of issuance costs   276    83,854 
Exercise of options and warrants   2,757    3,418 
Proceeds from issuance of convertible note   171,499     
Prepayment of forward stock repurchase transaction   (45,069)    
Payment of debt issuance costs   (4,991)    
Net cash provided by financing activities   124,472    87,272 
Effect of exchange rate on cash:   (56)   198 
Increase in cash and cash equivalents   38,297    43,365 
Cash and cash equivalents, beginning of period   28,513    19,244 
Cash and cash equivalents, end of period  $66,810   $62,609